Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
183
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 48 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 10 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 29, 1987 | Vinblastine | FDA US | cancer not stated in this record | I. Frequently Responsive Malignancies • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma •… | ORIGANDA089515 | approved | openfda |
| Apr 29, 1987 | Vinblastine | FDA US | Choriocarcinoma | Choriocarcinoma resistant to other chemotherapeutic agents | ORIGANDA089515 | approved | openfda |
| Apr 29, 1987 | Vinblastine | FDA US | Kaposi Sarcoma | Kaposi’s sarcoma | ORIGANDA089515 | approved | openfda |
| Apr 29, 1987 | Vinblastine | FDA US | Mycosis Fungoides | Mycosis fungoides (advanced stages) | ORIGANDA089515 | approved | openfda |
| Apr 29, 1987 | Vinblastine | FDA US | Hodgkin Lymphoma | Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) | ORIGANDA089515 | approved | openfda |
| Apr 29, 1987 | Cyclophosphamide | FDA US | cancer not stated in this record | Efficacy supplement 1987-04-29 (see label) | SUPPLNDA012141 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 30, 1986 | Etoposide | FDA US | Lung Small Cell Carcinoma | VePesid (etoposide) is indicated in the management of: Small Cell Lung Cancer— VePesid Capsules in combination with other approved… | ORIG |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 1, 1986 | Valproic Acid | FDA US | cancer not stated in this record | Epilepsy Valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 28, 1986 | Prednisolone | FDA US | cancer not stated in this record | Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 13, 1981 | Azathioprine | FDA US | cancer not stated in this record | Efficacy supplement 1981-04-13 (see label) | SUPPLNDA016324 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 19, 1978 | Cisplatin | FDA US | Malignant Bladder Neoplasm | INDICATIONS Cisplatin Injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 17, 1978 | Tretinoin | FDA US | cancer not stated in this record | Tretinoin is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this… | ORIGNDA017955 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 7, 1977 | Carmustine | FDA US | cancer not stated in this record | Carmustine for Injection, USP is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 4, 1976 | Lomustine | FDA US | cancer not stated in this record | Brain Tumors Gleostine is indicated for the treatment of patients with primary and metastatic brain tumors following appropriate surgical… | ORIGNDA017588 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 18, 1975 | Tretinoin | FDA US | cancer not stated in this record | RETIN-A is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this… | ORIGNDA017579 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 11, 1974 | Chloroquine | FDA US | cancer not stated in this record | Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum,… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 19, 1974 | Tretinoin | FDA US | cancer not stated in this record | Tretinoin is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this… | ORIGNDA017522 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 10, 1973 | Prednisolone | FDA US | cancer not stated in this record | : Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 30, 1973 | Prednisolone | FDA US | cancer not stated in this record | PRED FORTE ® is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and… | ORIGNDA017011 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 26, 1973 | Tretinoin | FDA US | cancer not stated in this record | Tretinoin is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this… | ORIGNDA017340 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 10, 1972 | Prednisolone | FDA US | cancer not stated in this record | PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva,… | ORIGNDA017100 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 17, 1972 | Prednisone | FDA US | cancer not stated in this record | Prednisone tablets, USP are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 29, 1970 | Fluorouracil | FDA US | cancer not stated in this record | Original approval 1970-07-29 — label text not available on openFDA | ORIGNDA016831 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 22, 1969 | Procarbazine | FDA US | Hodgkin Lymphoma | Matulane is indicated for use in combination with other anticancer drugs for the treatment of Stage III and IV Hodgkin's disease. Matulane… | ORIG |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 20, 1968 | Azathioprine | FDA US | cancer not stated in this record | : IMURAN is indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 7, 1967 | Hydroxyurea | FDA US | cancer not stated in this record | DROXIA is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in patients with sickle cell… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 18, 1966 | Thioguanine | FDA US | cancer not stated in this record | a) Acute Nonlymphocytic Leukemias TABLOID brand Thioguanine is indicated for remission induction and remission consolidation treatment of… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 20, 1962 | Dexamethasone | FDA US | cancer not stated in this record | Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 16, 1959 | Cyclophosphamide | FDA US | cancer not stated in this record | Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 10, 1959 | Methotrexate | FDA US | cancer not stated in this record | o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen. • Treatment of adults with… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 18, 1957 | Chlorambucil | FDA US | cancer not stated in this record | LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 18, 1955 | Hydroxychloroquine | FDA US | cancer not stated in this record | Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale , and Plasmodium vivax in adult and… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 26, 1954 | Busulfan | FDA US | Myeloid Leukemia | MYLERAN (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia. | ORIGNDA009386 | approved |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 11, 1953 | Mercaptopurine | FDA US | Acute Lymphoblastic Leukemia | 1 INDICATIONS & USAGE Mercaptopurine tablets is a nucleoside metabolic inhibitor indicated for treatment of adult and pediatric patients… |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approved |
| openfda |
| ORIGANDA070868 |
| approved |
| openfda |
| ORIGNDA019157 |
| approved |
| openfda |
| ORIGNDA018057 |
| approved |
| openfda |
| approved |
| openfda |
| ORIGNDA017422 |
| approved |
| openfda |
| approved |
| openfda |
| Aug 4, 1976 | Lomustine | FDA US | Hodgkin Lymphoma | Hodgkin's Lymphoma Gleostine is indicated as a component of combination chemotherapy for the treatment of patients with Hodgkin's lymphoma… | ORIGNDA017588 | approved | openfda |
| approved |
| openfda |
| ORIGANDA080880 |
| approved |
| openfda |
| approved |
| openfda |
| ORIGNDA017469 |
| approved |
| openfda |
| openfda |
| approved |
| openfda |
| approved |
| openfda |
| ORIGANDA080356 |
| approved |
| openfda |
| Jul 8, 1970 | Mitotane | FDA US | Adrenal Cortical Carcinoma | LYSODREN is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenocortical carcinoma (ACC). LYSODREN… | ORIGNDA016885 | approved | openfda |
| approved |
| openfda |
| ORIGNDA016324 |
| approved |
| openfda |
| ORIGNDA016295 |
| approved |
| openfda |
| ORIGNDA012429 |
| approved |
| openfda |
| ORIGNDA013422 |
| approved |
| openfda |
| ORIGNDA012141 |
| approved |
| openfda |
| ORIGNDA011719 |
| approved |
| openfda |
| Aug 10, 1959 | Methotrexate | FDA US | Head and Neck Squamous Cell Carcinoma | o Treatment of adults with squamous cell carcinoma of the head and neck as a single agent. | ORIGNDA011719 | approved | openfda |
| Aug 10, 1959 | Methotrexate | FDA US | Malignant Breast Neoplasm | o Treatment of adults with breast cancer as part of a combination chemotherapy regimen. | ORIGNDA011719 | approved | openfda |
| Aug 10, 1959 | Methotrexate | FDA US | Osteosarcoma | o Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. | ORIGNDA011719 | approved | openfda |
| Aug 10, 1959 | Methotrexate | FDA US | Non-Hodgkin Lymphoma | o Treatment of adult and pediatric patients with non-Hodgkin lymphoma. | ORIGNDA011719 | approved | openfda |
| Aug 10, 1959 | Methotrexate | FDA US | Meningeal Leukemia | o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia. | ORIGNDA011719 | approved | openfda |
| Aug 10, 1959 | Methotrexate | FDA US | Acute Lymphoblastic Leukemia | The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a… | ORIGNDA011719 | approved | openfda |
| ORIGNDA010669 |
| approved |
| openfda |
| ORIGNDA009768 |
| approved |
| openfda |
| openfda |
| ORIGNDA009053 |
| approved |
| openfda |